Boston Scientific today shared study data supporting the use of its Eluvia drug-eluting stent for treating PAD.

A recent review of 41 femoral arteriograms carried out at the Memorial Hospital, Worcester, indicated that 76 per cent showed an obstruction of the superficial femoral artery at this level (Fig.

Cordis announced new data from the SUCCESS PTA and SELUTION SFA Japan peripheral studies evaluating the company’s Selution ...

The Miami Lakes, Florida-based company presented 12-month results from the SUCCESS PTA study at the Charing Cross Symposium in London. It then shared SELUTION SFA Japan three-year results today at the ...

Following the successful completion of SIRONA--the largest superficial femoral artery (SFA) trial comparing our device against paclitaxel drug-coated balloons (DCBs), which demonstrated non ...

PTAB with the DETOUR System offers a novel approach to treating complex peripheral arterial disease (PAD), enabling physicians to percutaneously bypass lesions in the superficial femoral artery by ...

SELUTION SLR™ Drug-Eluting Balloon (DEB) achieves amongst the highest reported patency for any drug-eluting or drug-coated technology at 3 years in the SELUTION SFA Japan Trial, with 81.5% ...